These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 33209499)

  • 21. Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma.
    Hu Q; Wang D; Chen Y; Li X; Cao P; Cao D
    Radiat Oncol; 2019 Jul; 14(1):120. PubMed ID: 31291998
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Neoadjuvant chemotherapy or chemoradiotherapy for adenocarcinoma of the esophagus.
    Visser E; Edholm D; Smithers BM; Thomson IG; Burmeister BH; Walpole ET; Gotley DC; Joubert WL; Atkinson V; Mai T; Thomas JM; Barbour AP
    J Surg Oncol; 2018 Jun; 117(8):1687-1696. PubMed ID: 29806960
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Optimal Treatment Strategies for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma: A Real-World Triple Cohort Analysis Using Propensity Score Matching.
    Han D; Tian J; Zhao J; Hao S
    Int J Gen Med; 2023; 16():5467-5479. PubMed ID: 38021055
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neoadjuvant Chemoradiation Shows No Survival Advantage to Chemotherapy Alone in Stage IIIA Patients.
    Krantz SB; Mitzman B; Lutfi W; Kuchta K; Wang CH; Howington JA; Kim KW
    Ann Thorac Surg; 2018 Apr; 105(4):1008-1016. PubMed ID: 29453000
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of outcomes between neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy in patients with locally advanced esophageal cancer: A network meta-analysis.
    Fan N; Wang Z; Zhou C; Bludau M; Contino G; Zhao Y; Bruns C
    EClinicalMedicine; 2021 Dec; 42():101183. PubMed ID: 34805809
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influence of neoadjuvant therapy on outcomes in patients with resectable carcinoma of esophagus and gastro-esophageal junction from a tertiary cancer care center in India.
    Rao T S; Raju KVVN; Patnaik SC; Reddy P; Saksena AR; Rajappa S; Mallavarapu KM; Santa A; Gudipudi D; Boleneni N; Usofi Z; Gujjuru S; Smith L; Are C; Nusrath S
    J Surg Oncol; 2021 Jun; 123(7):1547-1557. PubMed ID: 33650697
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Perception versus reality: A National Cohort Analysis of the surgery-first approach for resectable pancreatic cancer.
    Bergquist JR; Thiels CA; Shubert CR; Ivanics T; Habermann EB; Vege SS; Grotz TE; Cleary SP; Smoot RL; Kendrick ML; Nagorney DM; Truty MJ
    Cancer Med; 2021 Sep; 10(17):5925-5935. PubMed ID: 34289264
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction.
    Klevebro F; Alexandersson von Döbeln G; Wang N; Johnsen G; Jacobsen AB; Friesland S; Hatlevoll I; Glenjen NI; Lind P; Tsai JA; Lundell L; Nilsson M
    Ann Oncol; 2016 Apr; 27(4):660-7. PubMed ID: 26782957
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adjuvant chemotherapy versus observation following neoadjuvant therapy and surgery for resectable stage I-II pancreatic cancer.
    Ma SJ; Serra LM; Bartl AJ; Han HR; Fekrmandi F; Iovoli AJ; Hermann GM; Yu H; Singh AK
    J Radiother Pract; 2022 Sep; 21(3):383-392. PubMed ID: 36016861
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Application of neoadjuvant chemoradiotherapy and neoadjuvant chemotherapy in curative surgery for esophageal cancer: A meta-analysis.
    Yuan MX; Cai QG; Zhang ZY; Zhou JZ; Lan CY; Lin JB
    World J Gastrointest Oncol; 2024 Jan; 16(1):214-233. PubMed ID: 38292844
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic Significance of Complete Pathologic Response Obtained with Chemotherapy Versus Chemoradiotherapy in Gastric Cancer.
    Trumbull DA; Lemini R; Díaz Vico T; Jorgensen MS; Attwood K; Ji W; Brady M; Gabriel E; Kukar M
    Ann Surg Oncol; 2021 Feb; 28(2):766-773. PubMed ID: 32737698
    [TBL] [Abstract][Full Text] [Related]  

  • 32. No Survival Difference with Neoadjuvant Chemoradiotherapy Compared with Chemotherapy in Resectable Esophageal and Gastroesophageal Junction Adenocarcinoma: Results from the National Cancer Data Base.
    Al-Sukhni E; Gabriel E; Attwood K; Kukar M; Nurkin SJ; Hochwald SN
    J Am Coll Surg; 2016 Dec; 223(6):784-792.e1. PubMed ID: 27641320
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of neoadjuvant radiotherapy on survival of non-metastatic pancreatic ductal adenocarcinoma: a SEER database analysis.
    Wang D; Liu C; Zhou Y; Yan T; Li C; Yang Q; Xu Y; Zhao L; Pei Q; Tan F; Güngör C; Li Y
    Radiat Oncol; 2020 May; 15(1):107. PubMed ID: 32404114
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of different neoadjuvant treatments for resectable locoregional esophageal cancer: A systematic review and network meta-analysis.
    Bao Y; Ma Z; Yuan M; Wang Y; Men Y; Hui Z
    Thorac Cancer; 2022 Sep; 13(17):2515-2523. PubMed ID: 35891585
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictors of Pathologic Response After Total Neoadjuvant Therapy in Patients With Rectal Adenocarcinoma: A National Cancer Database Analysis.
    McDermott DM; Singh SA; Renz PB; Hasan S; Weir J
    Cureus; 2021 Aug; 13(8):e17233. PubMed ID: 34540460
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Patient Risk Subgroups Predict Benefit of Adjuvant Chemotherapy in Stage II Rectal Cancer Patients Following Neoadjuvant Chemoradiation and Total Mesorectal Excision.
    Naffouje S; Sabesan A; Powers BD; Dessureault S; Sanchez J; Schell M; Imanirad I; Sahin I; Xie H; Felder S
    Clin Colorectal Cancer; 2021 Sep; 20(3):e155-e164. PubMed ID: 33775560
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adjuvant chemotherapy versus chemoradiation in high-risk pancreatic adenocarcinoma: A propensity score-matched analysis.
    Raoof M; Blakely AM; Melstrom LG; Lee B; Warner SG; Chung V; Singh G; Chen YJ; Fong Y
    Cancer Med; 2019 Oct; 8(13):5881-5890. PubMed ID: 31414566
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Impact of Signet Ring Cell Differentiation on Outcome in Patients with Esophageal and Gastroesophageal Junction Adenocarcinoma.
    van Hootegem SJM; Smithers BM; Gotley DC; Brosda S; Thomson IG; Thomas JM; Gartside M; van Lanschot JJB; Lagarde SM; Wijnhoven BPL; Barbour AP
    Ann Surg Oncol; 2019 Aug; 26(8):2375-2384. PubMed ID: 30941657
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Impact of Prolonged Chemotherapy to Surgery Interval and Neoadjuvant Radiotherapy on Pathological Complete Response and Overall Survival in Pancreatic Cancer Patients.
    Azab B; Macedo FI; Chang D; Ripat C; Franceschi D; Livingstone AS; Yakoub D
    Clin Med Insights Oncol; 2020; 14():1179554920919402. PubMed ID: 32669884
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The impact of neoadjuvant and adjuvant immunotherapy on the survival of pancreatic cancer patients: a retrospective analysis.
    Amin S; Baine M; Meza J; Lin C
    BMC Cancer; 2020 Jun; 20(1):538. PubMed ID: 32517661
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.